Related Experiment Video
Updated: Mar 31, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Nivolumab: a review in advanced squamous non-small cell lung cancer
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Abstract:
Nivolumab (Opdivo(®); Nivolumab BMS™) was the first programmed death (PD)-1 immune checkpoint inhibitor to be approved for use in advanced, squamous non-small cell lung cancer (NSCLC) following prior chemotherapy. In the pivotal CheckMate 017 trial, intravenous nivolumab 3 mg/kg every 2 weeks was associated with significantly better overall survival and progression-free survival and a significantly higher overall response rate than intravenous docetaxel in the second-line treatment of advanced, squamous NSCLC. Nivolumab was also better tolerated than docetaxel in CheckMate 017, and its adverse event profile (which included immune-mediated adverse events) was manageable. In conclusion, nivolumab represents an important advance in previously-treated, advanced, squamous NSCLC.
Insights
Nivolumab, a PD-1 inhibitor, significantly improved survival and response rates in advanced squamous non-small cell lung cancer (NSCLC) patients previously treated with chemotherapy. It also demonstrated a better safety profile compared to docetaxel.
Area of Science:
- Oncology
- Immunotherapy
- Thoracic Cancers
Background:
- Nivolumab was the first PD-1 inhibitor approved for advanced squamous non-small cell lung cancer (NSCLC) post-chemotherapy.
- Previous treatments for advanced squamous NSCLC often had limited efficacy and significant toxicity.
Purpose of the Study:
- To evaluate the efficacy and safety of nivolumab compared to docetaxel in previously treated advanced squamous NSCLC.
Main Methods:
- The pivotal CheckMate 017 trial compared intravenous nivolumab (3 mg/kg every 2 weeks) with intravenous docetaxel.
- Patient outcomes including overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) were assessed.
Main Results:
- Nivolumab demonstrated significantly superior OS and PFS compared to docetaxel.
- The overall response rate was significantly higher with nivolumab.
- Nivolumab exhibited a more favorable safety profile and was better tolerated than docetaxel, with manageable immune-mediated adverse events.
Conclusions:
- Nivolumab represents a significant therapeutic advancement for patients with previously treated, advanced, squamous NSCLC.
- The improved survival, response rates, and tolerability of nivolumab offer a new standard of care.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014